Abbott Laboratories (ABT) to Release Quarterly Earnings on Thursday

Abbott Laboratories (NYSE:ABT) is projected to post its Q4 2025 results before the market opens on Thursday, January 22nd. Analysts expect the company to announce earnings of $1.50 per share and revenue of $11.8006 billion for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, January 22, 2026 at 9:00 AM ET.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $121.05 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average price of $125.81 and a 200 day moving average price of $128.74. The firm has a market capitalization of $210.49 billion, a P/E ratio of 15.17, a PEG ratio of 2.02 and a beta of 0.72. Abbott Laboratories has a 52 week low of $113.50 and a 52 week high of $141.23.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.1%. Abbott Laboratories’s payout ratio is 31.58%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Turning Point Benefit Group Inc. bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $39,000. Triumph Capital Management acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $92,000. FSA Wealth Management LLC grew its stake in shares of Abbott Laboratories by 12.9% in the 3rd quarter. FSA Wealth Management LLC now owns 885 shares of the healthcare product maker’s stock valued at $119,000 after purchasing an additional 101 shares during the period. Riggs Asset Managment Co. Inc. lifted its holdings in shares of Abbott Laboratories by 9.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 88 shares during the period. Finally, McIlrath & Eck LLC grew its stake in Abbott Laboratories by 16.0% during the second quarter. McIlrath & Eck LLC now owns 1,122 shares of the healthcare product maker’s stock worth $153,000 after buying an additional 155 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Mizuho boosted their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, October 14th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. The Goldman Sachs Group dropped their target price on Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Abbott Laboratories in a report on Monday, December 29th. Finally, Barclays upped their target price on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $147.42.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.